-

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis. The Company will issue a press release tomorrow morning detailing these findings together with the optimized Stage 2 study design that will guide completion of the Phase 2 program.

Following the preliminary interim assessment announced in June, the Company conducted a detailed multi-week review of the Stage 1 dataset within the trial's adaptive framework. The review was overseen by Dr. Bruce Stouch, the study's lead biostatistician, and Dr. Stephen Hahn, Executive Clinical and Regulatory Lead, and evaluated efficacy and study design considerations to inform the design of Stage 2.

Webcast Details

Turn Therapeutics' live webcast will begin on Tuesday, July 7, 2026, at 4:30 p.m. ET. Bradley Burnam, Chief Executive Officer, and Dr. Hahn will host the call. The live webcast can be accessed via https://edge.media-server.com/mmc/p/jix773zk or the Investors section on the Company's website, https://ir.turntherapeutics.com. A replay of the webcast will be available following the call.

About Turn Therapeutics

Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics' lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression.

Contacts

Investor Relations / Media Contact
Sasha Damouni Ellis
The Damouni Group
Sasha@damounigroup.com

Turn Therapeutics, Inc.

NASDAQ:TTRX

Release Versions

Contacts

Investor Relations / Media Contact
Sasha Damouni Ellis
The Damouni Group
Sasha@damounigroup.com

More News From Turn Therapeutics, Inc.

Turn Therapeutics to Present at Jefferies Global Healthcare Conference in London

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, will deliver a company presentation as part of the Jefferies Global Healthcare Conference in London. Presentation details are as follows: Date: Monday, November 16, 2026 Time: 10:30 AM – 10:55 AM ET (3:30 PM – 3:55 PM GMT) The Company will...

Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and nine months ended September 30, 2026. Additional Stage 1/Phase 2a results show encouraging response in the full atopic dermatitis trial population In October 2026, Turn Therapeutics reported additional res...

Turn Therapeutics’ GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that GX-03 has been selected as “Developmental Immunology Solution of the Year” in the sixth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and bio...
Back to Newsroom